Associated Papers
Genetic landscape and therapeutic evolution of cyclophosphamide: spotlight on breast cancer.
Cao J et al.
Journal of Chemotherapy (florence, Italy), 2025
Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients.
Shenoy PV et al.
Cancer Metastasis Reviews, 2025
Decoding the Impact of Genetic Polymorphisms in Xenobiotic Metabolizing Enzymes and Ovarian Cancer: A Comprehensive Review.
Sistla HC et al.
Environmental and Molecular Mutagenesis, 2025
An Investigational Study on the Role of ADME Agents' Genetic Variation on DD217 Pharmacokinetics and Safety Profile.
Sychev DA et al.
Pharmaceuticals (basel, Switzerland), 2025
Impact of Xenobiotic Detoxification Gene Polymorphisms on Steady-State Plasma Concentrations of Apixaban and the Development of Hemorrhagic Complications in Older Patients with Non-Valvular Atrial Fibrillation.
Kondrakhin AP et al.
Genes, 2025
Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health.
Naderi N et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2025
Genetic Modulation of Silodosin Exposure and Efficacy: The Role of CYP3A4, CYP3A5, and UGT2B7 Polymorphisms in Benign Prostatic Hyperplasia Management.
Abdullaev SP et al.
Journal of Personalized Medicine, 2025
Human iPSC-based breast cancer model identifies S100P-dependent cancer stemness induced by BRCA1 mutation.
Liu J et al.
Science Advances, 2025
Impact of ABCB1 single-nucleotide variants on early, extremely severe neutropenia induced by paclitaxel/nanoparticle albumin-bound paclitaxel in patients with gastric cancer.
Maeda A et al.
British Journal of Clinical Pharmacology, 2025
Analgesic therapy failure in a COMT HPS/HPS diplotype carrier heterozygous for the CYP2D6 *4 allele with fibromyalgia-a case report.
Bollinger A et al.
Pain Reports, 2025
ABCB1 gene single nucleotide variants and haplotypes in atrial fibrillation patients experiencing adverse events on direct oral anticoagulation: a whole gene exome sequencing study.
Samoš M et al.
Journal of Cardiovascular Pharmacology, 2025
The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.
Cacabelos R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
Genetic variants and clinical determinants affecting the response to 5-Fluorouracil-based treatment in Chilean patients with advanced colorectal cancer.
Cerpa LC et al.
Frontiers in Oncology, 2025
Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol.
Salazar J et al.
Pharmaceutics, 2024
Computational Analysis of MDR1 Variants Predicts Effect on Cancer Cells via their Effect on mRNA Folding.
Gutman T et al.
Plos Computational Biology, 2024
Pharmacogenotyping disproves genetic cause of drug-related problems in family history: a case report.
Bollinger A et al.
Bmc Anesthesiology, 2024
CYP3A4*1B but Not CYP3A5*3 as Determinant of Long-Term Tacrolimus Dose Requirements in Spanish Solid Organ Transplant Patients.
Concha J et al.
International Journal of Molecular Sciences, 2024
Successful rapid improvement of acute respiratory distress syndrome induced by EGFR-mutated non-small cell lung cancer with almonertinib: a case report.
Sun C et al.
Bmc Pulmonary Medicine, 2024
Challenging pharmacotherapy management of a psychotic disorder due to a delicate pharmacogenetic profile and drug-drug interactions: a case report and literature review.
Belančić A et al.
Croatian Medical Journal, 2024
ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer.
Barba A et al.
Pharmaceutics, 2024
Characterization of Chemoresistance in Pancreatic Cancer: A Look at MDR-1 Polymorphisms and Expression in Cancer Cells and Patients.
Girolimetti G et al.
International Journal of Molecular Sciences, 2024
Major Genetic Drivers of Statin Treatment Response in African Populations and Pharmacogenetics of Dyslipidemia Through a One Health Lens.
Lusiki Z et al.
Omics : a Journal of Integrative Biology, 2024
A systematic review and meta-analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer.
Lingaratnam S et al.
Clinical and Translational Science, 2024
Breast cancer resistance protein polymorphism ABCG2 c.421C>A (rs2231142) moderates the effect of valproate on lamotrigine trough concentrations in adults with epilepsy.
Šušak Sporiš I et al.
Fundamental & Clinical Pharmacology, 2024
Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy.
Ma Y et al.
Clinical Pharmacokinetics, 2024
Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced Colorectal Cancer Patients: An Exploratory Study.
Cayún JP et al.
Current Oncology (toronto, Ont.), 2024
Case report: Avoiding intolerance to antipsychotics through a personalized treatment approach based on pharmacogenetics.
Korošec Hudnik L et al.
Frontiers in Psychiatry, 2024
Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Li X et al.
European Journal of Pediatrics, 2023
Pharmacogenetic Variants Associated with Fluoxetine Pharmacokinetics from a Bioequivalence Study in Healthy Subjects.
Díaz-Tufinio CA et al.
Journal of Personalized Medicine, 2023
Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7 -161C > T (rs7668258) or UGT1A4*3 c.142 T > G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy.
Božina N et al.
European Journal of Clinical Pharmacology, 2023
Importance of Pharmacogenetics and Drug-Drug Interactions in a Kidney Transplanted Patient.
Concha J et al.
Life (basel, Switzerland), 2023
Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review.
Cura Y et al.
Cancers, 2023
Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18).
Maeda A et al.
Anticancer Research, 2023
Pharmacogenetics of anxiety and depression in Alzheimer's disease.
Cacabelos R et al.
Pharmacogenomics, 2023
Case report: Hepatotoxicity and nephrotoxicity induced by methotrexate in a paediatric patient, what is the role of precision medicine in 2023?
El Masri AER et al.
Frontiers in Pharmacology, 2023
Analytical validation of GenoPharm a clinical genotyping open array panel of 46 pharmacogenes inclusive of variants unique to people of African ancestry.
Kanji CR et al.
Plos One, 2023
Polymorphisms in drug metabolism genes predict the risk of refractory myasthenia gravis.
Zhang Q et al.
Annals of Translational Medicine, 2022
Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis.
Alves R et al.
International Journal of Molecular Sciences, 2022
Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib.
Maeda A et al.
European Journal of Clinical Pharmacology, 2022
Composite CYP3A phenotypes influence tacrolimus dose-adjusted concentration in lung transplant recipients.
Liu M et al.
Pharmacogenetics and Genomics, 2022
Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers.
Bignucolo A et al.
Expert Review of Clinical Pharmacology, 2022
Potential genetic biomarker of Saudi Arabian patients with colorectal cancer.
Younis NS et al.
European Review for Medical and Pharmacological Sciences, 2022
Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.
Pinto-Merino Á et al.
Pharmaceutics, 2022
Pharmacogenetics of Drugs Used in the Treatment of Cancers.
Franczyk B et al.
Genes, 2022
Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics.
Hirvensalo P et al.
Clinical and Translational Science, 2022